Cargando…

First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics

AIMS: Neuronal hypersensitisation due to adenosine triphosphate‐dependent P2X3 receptor signalling plays a significant role in several disorders including chronic cough and endometriosis. This first‐in‐human study of eliapixant (BAY 1817080) investigated the tolerability, safety and pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Stefan, Gashaw, Isabella, Baumann, Sybille, Chang, Xinying, Hummel, Thomas, Thuß, Uwe, Friedrich, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546310/
https://www.ncbi.nlm.nih.gov/pubmed/35437837
http://dx.doi.org/10.1111/bcp.15358
_version_ 1784805013074214912
author Klein, Stefan
Gashaw, Isabella
Baumann, Sybille
Chang, Xinying
Hummel, Thomas
Thuß, Uwe
Friedrich, Christian
author_facet Klein, Stefan
Gashaw, Isabella
Baumann, Sybille
Chang, Xinying
Hummel, Thomas
Thuß, Uwe
Friedrich, Christian
author_sort Klein, Stefan
collection PubMed
description AIMS: Neuronal hypersensitisation due to adenosine triphosphate‐dependent P2X3 receptor signalling plays a significant role in several disorders including chronic cough and endometriosis. This first‐in‐human study of eliapixant (BAY 1817080) investigated the tolerability, safety and pharmacokinetics (PK) of single doses of eliapixant, including the effect of food and coadministration with a CYP3A inhibitor on eliapixant relative bioavailability. METHODS: In this randomised, double‐blind phase I study (NCT02817100), 88 healthy male subjects received single ascending doses of immediate‐release eliapixant (10–800 mg) tablets or placebo under fasted conditions, with food (low‐fat continental or high‐fat American breakfast) or with itraconazole (fasted state). PK parameters, dose proportionality, adverse events and taste assessments (taste strips; dysgeusia questionnaire) were evaluated. RESULTS: Eliapixant had a long half‐life (23.5–58.9 h [fasted state]; 32.8–43.8 h [high‐fat breakfast]; 38.9–46.0 h [low‐fat breakfast]). Less than dose‐proportional increases in maximum plasma concentrations (C(max)) and area under the concentration–time curve from time 0 to infinity (AUC([0–inf])) were observed with ascending eliapixant doses. We observed a pronounced food effect with the high‐fat breakfast (4.1‐fold increased C(max); 2.7‐fold increased AUC([0–inf])), a smaller food effect with the low‐fat breakfast and a mild‐to‐moderate effect of itraconazole coadministration on eliapixant (1.1–1.2‐fold increased C(max); 1.7‐fold increased AUC from 0 to 72 h). Eliapixant was well tolerated with minimal impact on taste perception. CONCLUSION: The PK profile, particularly the long half‐life, and favourable tolerability with no taste‐related adverse events, supports the further development of eliapixant in disorders with underlying P2X3 receptor‐mediated neuronal hypersensitisation.
format Online
Article
Text
id pubmed-9546310
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95463102022-10-14 First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics Klein, Stefan Gashaw, Isabella Baumann, Sybille Chang, Xinying Hummel, Thomas Thuß, Uwe Friedrich, Christian Br J Clin Pharmacol Original Articles AIMS: Neuronal hypersensitisation due to adenosine triphosphate‐dependent P2X3 receptor signalling plays a significant role in several disorders including chronic cough and endometriosis. This first‐in‐human study of eliapixant (BAY 1817080) investigated the tolerability, safety and pharmacokinetics (PK) of single doses of eliapixant, including the effect of food and coadministration with a CYP3A inhibitor on eliapixant relative bioavailability. METHODS: In this randomised, double‐blind phase I study (NCT02817100), 88 healthy male subjects received single ascending doses of immediate‐release eliapixant (10–800 mg) tablets or placebo under fasted conditions, with food (low‐fat continental or high‐fat American breakfast) or with itraconazole (fasted state). PK parameters, dose proportionality, adverse events and taste assessments (taste strips; dysgeusia questionnaire) were evaluated. RESULTS: Eliapixant had a long half‐life (23.5–58.9 h [fasted state]; 32.8–43.8 h [high‐fat breakfast]; 38.9–46.0 h [low‐fat breakfast]). Less than dose‐proportional increases in maximum plasma concentrations (C(max)) and area under the concentration–time curve from time 0 to infinity (AUC([0–inf])) were observed with ascending eliapixant doses. We observed a pronounced food effect with the high‐fat breakfast (4.1‐fold increased C(max); 2.7‐fold increased AUC([0–inf])), a smaller food effect with the low‐fat breakfast and a mild‐to‐moderate effect of itraconazole coadministration on eliapixant (1.1–1.2‐fold increased C(max); 1.7‐fold increased AUC from 0 to 72 h). Eliapixant was well tolerated with minimal impact on taste perception. CONCLUSION: The PK profile, particularly the long half‐life, and favourable tolerability with no taste‐related adverse events, supports the further development of eliapixant in disorders with underlying P2X3 receptor‐mediated neuronal hypersensitisation. John Wiley and Sons Inc. 2022-05-22 2022-10 /pmc/articles/PMC9546310/ /pubmed/35437837 http://dx.doi.org/10.1111/bcp.15358 Text en © 2022 Bayer AG. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Klein, Stefan
Gashaw, Isabella
Baumann, Sybille
Chang, Xinying
Hummel, Thomas
Thuß, Uwe
Friedrich, Christian
First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics
title First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics
title_full First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics
title_fullStr First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics
title_full_unstemmed First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics
title_short First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics
title_sort first‐in‐human study of eliapixant (bay 1817080), a highly selective p2x3 receptor antagonist: tolerability, safety and pharmacokinetics
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546310/
https://www.ncbi.nlm.nih.gov/pubmed/35437837
http://dx.doi.org/10.1111/bcp.15358
work_keys_str_mv AT kleinstefan firstinhumanstudyofeliapixantbay1817080ahighlyselectivep2x3receptorantagonisttolerabilitysafetyandpharmacokinetics
AT gashawisabella firstinhumanstudyofeliapixantbay1817080ahighlyselectivep2x3receptorantagonisttolerabilitysafetyandpharmacokinetics
AT baumannsybille firstinhumanstudyofeliapixantbay1817080ahighlyselectivep2x3receptorantagonisttolerabilitysafetyandpharmacokinetics
AT changxinying firstinhumanstudyofeliapixantbay1817080ahighlyselectivep2x3receptorantagonisttolerabilitysafetyandpharmacokinetics
AT hummelthomas firstinhumanstudyofeliapixantbay1817080ahighlyselectivep2x3receptorantagonisttolerabilitysafetyandpharmacokinetics
AT thußuwe firstinhumanstudyofeliapixantbay1817080ahighlyselectivep2x3receptorantagonisttolerabilitysafetyandpharmacokinetics
AT friedrichchristian firstinhumanstudyofeliapixantbay1817080ahighlyselectivep2x3receptorantagonisttolerabilitysafetyandpharmacokinetics